Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Immunotherapy with ICIs is a promising treatment for elderly NSCLC patients, offering a balance of efficacy and safety. This methodology provides a comprehensive framework for assessing the outcomes of immunotherapy in elderly NSCLC patients, focusing on survival rates, response rates and treatment‐related toxicity. The use of retrospective data and statistical analyses allows for the evaluation of real‐world effectiveness and safety of immunotherapy in this population. First‐line treatment comprised chemotherapy in 70.4%), IO immunotherapy in (18.7%) and targeted therapy in 13.5%. Among chemotherapy‐treated patients, 674 (96.6%) received platinum‐based chemotherapy and carboplatin‐based doublet or triplet chemotherapy was the most commonly administered regimen 72.4% of chemotherapy‐treated patients]. In the overall population, patients (29.5%) received 2 L therapy, which was chemotherapy in (37.1%), IO monotherapy in (52.5%) and targeted therapy in (13.1%). Immunotherapy remains a viable and effective treatment option for elderly NSCLC patients, with age alone not being a limiting factor. The decision to use ICIs should consider the patient's overall health and performance status rather than age alone, and further research is needed to optimize treatment strategies for this growing patient population.
How to cite this article:
K.P. Selvarajan Chettiar and R. Aashish. Outcomes of Immunotherapy in Elderly Patients with Non Small Cell Lung Cancer: A Retrospective Analysis.
DOI: https://doi.org/10.36478/10.36478/makrjms.2025.1.353.357
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2025.1.353.357